Long-Term Follow Up of VOY-101 Non-nAMD Extension Study

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Perceive Biotherapeutics, Inc.
Study ID
NCT07660640
Status
Enrolling By Invitation

Conditions

  • Age-Related Macular Degeneration (AMD)
  • Non-Neovascular Age-Related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • observational study — OTHER
    No intervention - observational study
  • VOY-101 — BIOLOGICAL
    One-time intravitreal injection of VOY-101.

Study Details

Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration

Key Dates

Start date
Mar 3, 2026
Status verified
Feb 2026
Primary completion
Jul 30, 2031
Completion
Aug 30, 2031

Study Design

Enrollment
88 participants (estimated)

Arms

  • Arm: Rollover from PBI-AMD-001 and PBI-AMD-002 studies for those participants who received VOY-101
    Long-term safety extension from PBI-AMD-001 and PBI-AMD-002 studies for those participants who received VOY-101

Primary Outcome Measure

Frequency of ocular and systemic VOY-101 related AEs [ Time Frame: 3 years ]

Locations (3)

FacilityCityStateZIPSite coordinators
Ophthalmic Consultants of BostonBostonMassachusetts02114-
Retina Consultants of TexasBellaireTexas77401-
University of UtahSalt Lake CityUtah84132-

Find similar trials in Boston, MA

By research site
Ophthalmic Consultants of Boston· Boston, MARetina Consultants of Texas· Bellaire, TXUniversity of Utah· Salt Lake City, UT

Related Studies